Newsfeed

Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients
Chronic thromboembolic pulmonary hypertension (CTEPH) is associated with chronic inflammation but the pathological mechanisms are largely unknown. Our study aimed to simultaneously profile a broad range of cytokines in the supernatant of pulmonary endarterectomy (PEA) surgical material, as well as prospectively in patients with CTEPH to investigate whether circulating cytokines are associated with haemodynamic and physical characteristics of CTEP…
New Targets For PAH Treatments Identified By Researchers
A new study published in September’s issue of the American Journal of Respiratory and Critical Care Medicine, entitled, “The Sphingosine Kinase 1 / Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension” reports the discovery of two novel therapeutic targets to treat pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a result of elevated blood pressure in the arteries that supply the lungs, causing their walls …
Sarcoidosis-Associated Pulmonary Hypertension Highlighted By Recent Study
While a major population of pulmonary hypertension patients are diagnosed with idiopathic or arterial pulmonary hypertension, a population of patients with pulmonary hypertension patients due to sarcoidosis is no less affected by the condition. Estimates from a paper published in Seminars in Respiratory and Critical Care Medicine state that approximately 6-20% of sarcoidosis patients will develop pulmonary hypertension and see an increased risk o…
Bayer’s Adempas For CTEPH, PAH Confirmed Safe & Effective in Long-Term Studies
Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress. Riociguat is the first member of a new class of soluble guanylate cyclase (sGC) stimulators tha…
Researchers find new targets for treating pulmonary hypertension
Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago. Their findings are reported in the American Journal of Respiratory and Critical Care Medicine. Early symptoms of pulmonary arterial hypertension include shortness of breath and exercise intolerance. As the disease progr…
First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study
-- AMBITION Study of Ambrisentan/Tadalafil Combination Therapy Versus Monotherapy Achieves Primary Endpoint of Time to First Clinical Failure Event -- -- Data Presented at the ERS International Congress 2014 -- MUNICH--(BUSINESS WIRE)--Sep. 8, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalaf…
Protein in 'good cholesterol' may be a key to treating pulmonary hypertension
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs. Using a rodent model, the researchers showed that a peptide mimicking part of the main protein in high-density lipoprotein (HDL), the so-called…
New Report Identifies Key Features in Systemic Sclerosis
Systemic sclerosis (SSc) is a disease that affects multiple organs, with the heart being frequently affected and correlating with a poor outcome for the patient. Different heart structures can be affected leading to pericardial disease, arrhythmias, conduction system abnormalities, direct myocardial disease such as pulmonary arterial hypertension, myositis, cardiac failure, cardiac fibrosis, coronary artery diseases and, sometimes, primary valvul…
Novel Nitric Oxide Delivery System May Someday Improve PH Treatments
GeNo LLC, a pharmaceutical company developing a line of innovative nitric oxide drug products, is currently testing next-generation inhaled nitric oxide (NO) drug delivery systems for use in both hospital and outpatient settings that could come to impact treatments for those with pulmonary hypertension. Nitric oxide is a naturally occurring cellular signaling molecule that can function as an important biological regulator and has a crucial role …
New Pediatric PAH Goals For Treatment Could Improve Patient Outcomes
A team of researchers from the University Medical Center Groningen in Holland, has identified three baseline variables that can become treatment goals in children suffering with pulmonary arterial hypertension (PAH). PAH is rare in infants, however, it is a severe condition that rapidly deteriorates if left untreated. Pediatric PAH can be idiopathic PAH (IPAH), heritable PAH, or associated with congenital heart disease (PAH-CHD). Common symptom…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png